Please assess the completion status of the following clinical trial:

Trial Title: TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Active moderate to severe rheumatoid arthritis according to the revised (1987) American College of Rheumatology (ACR) criteria or EULAR/ACR (2010) criteria~* Inadequate response or intolerant to previous therapy with two or more non-biologic disease-modifying anti-rheumatic drugs (DMARDs), one of which is methotrexate, administered in an optimal way during at least 3 months; eligible participants may also be inadequate responders to a maximum of one biologic DMARD~* Oral corticosteroids (\</= 10 milligram per day (mg/day) prednisolone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to the recommended dose) are permitted if on stable dose regimen for \>/= 4 weeks prior to baseline~* Permitted DMARDs are allowed if at stable dose for at least 4 weeks prior to baseline~* Receiving treatment on an outpatient basis, not including tocilizumab~* Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception as defined by protocol~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline or during long term extension (LTE) period~* Rheumatic autoimmune disease other than rheumatoid arthritis~* Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis~* Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16~* Prior history of or current inflammatory joint disease other than RA~* Exposure to tocilizumab (intravenous or subcutaneous) at any time prior to baseline~* Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening~* Intraarticular or parenteral corticosteroids within 4 weeks prior to baseline~* History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies~* Evidence of serious concomitant disease or disorder~* Known active current or history of recurrent infection~* Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening~* Active Tuberculosis (TB) requiring treatment within the previous 3 years~* Positive for hepatitis B or hepatitis C~* Primary or secondary immunodeficiency (history of or currently active)~* Pregnant or lactating women~* Neuropathies or other conditions that might interfere with pain evaluation~* Inadequate hematologic, renal or liver function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).